세계의 말초혈관 기기 시장 : 유형별, 지역별 - 예측(-2029년)

The global Peripheral vascular devices market is projected to reach USD 14.73 billion by 2029 from USD 11.43 billion in 2024, at a CAGR of 5.2% from 2024 to 2029. The market for peripheral vascular devices is sharply increasing in view of an increased prevalence of vascular diseases such as PAD and DVT. Other key drivers for this expansion are an aging population base, increased adoption of less-invasive procedures, and advancements in vascular technology in stents, angioplasty balloons, and catheters. Increased awareness about timely diagnosis and treatment options and supportive initiatives from the government further increase market demand. Improvement in global healthcare infrastructure and an increased number of specialized vascular clinics are adding to upward movement of the market.

"By type segment Angioplasty stent to account for the largest share during the forecast period"

The peripheral vascular devices market offers a higher share of stents used in the treatment of angioplasty mainly because stenting is vital in managing diseases such as PAD and CAD. Stents are designed to give long-term vessel support where by the lumen of the arteries needs to be maintained after having a balloon angioplasty. Unlike balloons or catheters, stents are not used only during procedures; they are a permanent solution to the narrowing of an artery, decreasing the chances of restenosis. Technological advancements employing drug-eluting stents (DES) and bioresorbable stents have enhanced the capability of stents by lowering complications and yielding a better prognosis in the long term, therefore making it highly popular.

Stents are also increasingly gaining popularity because they are minimally invasive, where time towards recovery by patients and even the number of days spent in hospitals can be reduced compared to EVAR, or Endovascular Aneurysm Repair traditional surgical methods. Moreover, since the incidence of cardiovascular diseases and pay policies on stent procedures are rapidly moving in a healthy and benign direction, stent stints take the lead. Moreover, given the large geriatric population, where revascularization needs keep soaring, angioplasty stents remain the market leader for peripheral vascular devices.

"APAC is estimated to register the highest CAGR during the forecast period."

The Peripheral vascular devices market is divided into Five regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The Asia Pacific region witnessed the highest CAGR during the forecast period. Many APAC countries, including Japan, South Korea, and China, are witnessing demographic shifts as their populations age. The increasing diabetic population and increase in obesity due to sedentary lifestyles reassesses also driving the growth of peripheral vascular devices in the APAC region.

The breakdown of the profile of primary participants in the peripheral vascular devices market:

• By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
• By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
• By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%

List of Companies Profiled in the Report

• Boston scientific corporation(U.S)
• Medtronic (U.S)
• Abbott (U.S)
• Becton, Dickinson, and Company(U.S)
• Terumo Corporation (Japan)
• B. Braun Melsungen AG(Germany)
• Merit medical systems(U.S)
• Penumbra, inc.(U.S)
• Koninklijke Philips N.V..(Japan)

Research Coverage

This report studies the Peripheral vascular devices market based on type and region. The report also analyses factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets concerning their growth trends, prospects, and contributions to the total Peripheral vascular devices market. The report forecasts the revenue of the market segments to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (technological advancements), restraints (Cost of the system), challenges (regulatory policies), and opportunities (Increase in minimally invasive procedures) contributing to the growth of the Peripheral vascular devices market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, in the Peripheral vascular devices market.
• Market Development: Comprehensive information on the lucrative emerging markets type and region.
• Market Diversification: Exhaustive information about the growing geographies, recent developments, and investments in the Peripheral vascular devices market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global Peripheral vascular devices market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 LIMITATIONS
• 1.5 MARKET STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 MARKET SHARE ANALYSIS
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 PERIPHERAL VASCULAR DEVICES MARKET OVERVIEW
• 4.2 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE AND COUNTRY (2023)
• 4.3 PERIPHERAL VASCULAR DEVICES MARKET: GEOGRAPHIC SNAPSHOT

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rapid growth in geriatric population and subsequent increase in disease prevalence
    • 5.2.1.2 Favorable reimbursement scenario for procedures
    • 5.2.1.3 Increased prevalence of diabetes
    • 5.2.1.4 Rising rate of tobacco consumption
    • 5.2.1.5 Growing incidence of obesity
  • 5.2.2 OPPORTUNITIES
    • 5.2.2.1 High growth potential in emerging markets
  • 5.2.3 CHALLENGES
    • 5.2.3.1 Availability of alternative treatments
    • 5.2.3.2 Dearth of skilled professionals with expertise in peripheral vascular devices
    • 5.2.3.3 Product failures and recalls
• 5.3 INDUSTRY TRENDS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 PORTER'S FIVE FORCE ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS
  • 5.8.2 BUYING CRITERIA
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Drug-eluting stents
    • 5.9.1.2 Atherectomy devices
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Intravascular ultrasound
    • 5.9.2.2 Optical coherence tomography
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Remote patient monitoring
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY ANALYSIS
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 Japan
      • 5.10.1.3.2 China
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA
  • 5.11.2 EXPORT DATA
• 5.12 PRICING ANALYSIS
  • 5.12.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.12.2 AVERAGE SELLING PRICE, BY KEY PLAYERS
• 5.13 REIMBURSEMENT ANALYSIS
• 5.14 PATENT ANALYSIS
  • 5.14.1 PATENT PUBLICATION TRENDS
  • 5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.15 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.16 CASE STUDIES
  • 5.16.1 CASE STUDY 1: DRUG-COATED BALLOON HELPING IN REDUCING RESTENOSIS
  • 5.16.2 CASE STUDY 2: IMPROVED OUTCOMES WITH TERUMO'S MISAGO STENT
• 5.17 UNMET NEEDS AND END-USER EXPECTATIONS
  • 5.17.1 UNMET NEEDS
  • 5.17.2 END-USER EXPECTATIONS
• 5.18 INVESTMENT & FUNDING SCENARIO
• 5.19 IMPACT OF AI ON PERIPHERAL VASCULAR DEVICES MARKET

6 PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE

• 6.1 INTRODUCTION

7 ANGIOPLASTY STENTS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 DRUG-ELUTING STENTS
  • 7.2.1 DRUG-ELUTING STENTS TO WITNESS HIGHER ADOPTION
• 7.3 BARE-METAL STENTS
  • 7.3.1 BARE-METAL STENTS, BY DELIVERY PLATFORM
    • 7.3.1.1 Balloon-expandable stents
      • 7.3.1.1.1 Better radial strength and ease of deployment to drive usage
    • 7.3.1.2 Self-expandable stents
      • 7.3.1.2.1 Flexibility, tolerance, and support for vessel movement and compression to propel market

8 ENDOVASCULAR ANEURYSM REPAIR STENT GRAFTS MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 ABDOMINAL AORTIC ANEURYSM STENT GRAFTS
  • 8.2.1 RISING PREVALENCE AND NEED FOR TREATMENT TO DRIVE MARKET
• 8.3 THORACIC AORTIC ANEURYSM STENT GRAFTS
  • 8.3.1 INCREASING INCIDENCE OF THORACIC AORTIC ANEURYSMS TO PROPEL ADOPTION

9 CATHETERS MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 ANGIOGRAPHY CATHETERS
  • 9.2.1 ANGIOGRAPHY CATHETERS TO DOMINATE CATHETERS MARKET
• 9.3 GUIDING CATHETERS
  • 9.3.1 GROWING NUMBER OF TARGET PROCEDURES TO DRIVE MARKET
• 9.4 IVUS/OCT CATHETERS
  • 9.4.1 IVUS/OCT CATHETERS SEGMENT TO REGISTER HIGHEST GROWTH

10 INFERIOR VENA CAVA FILTERS MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 RETRIEVABLE FILTERS
  • 10.2.1 RETRIEVABLE FILTERS SEGMENT TO REGISTER HIGHER GROWTH
• 10.3 PERMANENT FILTERS
  • 10.3.1 RISKS ASSOCIATED WITH PERMANENT FILTERS TO HAMPER SALES

11 ANGIOPLASTY BALLOONS MARKET, BY TYPE

• 11.1 INTRODUCTION
• 11.2 OLD/NORMAL BALLOONS
  • 11.2.1 OLD/NORMAL BALLOONS TO DOMINATE ANGIOPLASTY BALLOONS MARKET
• 11.3 DRUG-ELUTING BALLOONS
  • 11.3.1 DRUG-ELUTING BALLOONS TO WITNESS HIGHEST GROWTH
• 11.4 CUTTING & SCORING BALLOONS
  • 11.4.1 PREFERENCE FOR MEDICATION AS PRIMARY TREATMENT FOR ATHEROSCLEROSIS TO RESTRAIN ADOPTION

12 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE

• 12.1 INTRODUCTION
• 12.2 ATHERECTOMY DEVICES
  • 12.2.1 INCREASING INCIDENCE OF ATHEROSCLEROSIS TO DRIVE MARKET
• 12.3 THROMBECTOMY DEVICES
  • 12.3.1 GROWING DVT INCIDENCE TO DRIVE ADOPTION OF THROMBECTOMY DEVICES

13 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE

• 13.1 INTRODUCTION
• 13.2 EMBOLIC PROTECTION DEVICES
  • 13.2.1 INVESTMENTS IN TECHNOLOGICAL ADVANCEMENTS AND GROWING REGULATORY APPROVALS TO DRIVE MARKET
• 13.3 CHRONIC TOTAL OCCLUSION DEVICES
  • 13.3.1 RISING SUPPORT FOR DEVICE DEVELOPMENT TO DRIVE MARKET

14 OTHER PERIPHERAL VASCULAR DEVICES MARKET, BY TYPE

• 14.1 INTRODUCTION
• 14.2 GUIDEWIRES
  • 14.2.1 GUIDEWIRES TO HOLD LARGEST MARKET SHARE
• 14.3 VASCULAR CLOSURE DEVICES
  • 14.3.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
• 14.4 INTRODUCER SHEATHS
  • 14.4.1 POTENTIAL FOR REDUCING ARTERIAL DAMAGE TO DRIVE ADOPTION
• 14.5 BALLOON INFLATION DEVICES
  • 14.5.1 INTEGRATED TECHNOLOGIES AND RISING NUMBER OF TARGET PROCEDURES TO PROPEL ADOPTION

15 PERIPHERAL VASCULAR DEVICES MARKET, BY REGION

• 15.1 INTRODUCTION
• 15.2 NORTH AMERICA
  • 15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 15.2.2 US
    • 15.2.2.1 Favorable reimbursement scenario to contribute to growth
  • 15.2.3 CANADA
    • 15.2.3.1 Increasing cases of chronic conditions to fuel market
• 15.3 EUROPE
  • 15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 15.3.2 GERMANY
    • 15.3.2.1 Statutory health insurance policy to support growth
  • 15.3.3 FRANCE
    • 15.3.3.1 Growing geriatric population to drive market
  • 15.3.4 UK
    • 15.3.4.1 Increasing volume of coronary angioplasty procedures to sustain growth
  • 15.3.5 SPAIN
    • 15.3.5.1 Growing cases of diabetes and obesity to boost market
  • 15.3.6 ITALY
    • 15.3.6.1 Increasing prevalence of atherosclerotic cardiovascular disease to spur growth
  • 15.3.7 REST OF EUROPE
• 15.4 ASIA PACIFIC
  • 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 15.4.2 JAPAN
    • 15.4.2.1 Large geriatric population to ensure sustained demand
  • 15.4.3 CHINA
    • 15.4.3.1 Growing incidence of lifestyle diseases to fuel market
  • 15.4.4 INDIA
    • 15.4.4.1 Rising prevalence of target diseases and growing healthcare expenditure to propel market
  • 15.4.5 AUSTRALIA
    • 15.4.5.1 High prevalence of cardiovascular and peripheral artery diseases to drive market
  • 15.4.6 SOUTH KOREA
    • 15.4.6.1 Rising rates of chronic diseases to boost market
  • 15.4.7 REST OF ASIA PACIFIC
• 15.5 LATIN AMERICA
  • 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 15.5.2 BRAZIL
    • 15.5.2.1 Rising healthcare expenditure to aid growth
  • 15.5.3 MEXICO
    • 15.5.3.1 Increasing prevalence of cardiovascular diseases to spur growth
  • 15.5.4 COLOMBIA
    • 15.5.4.1 Growing incidence of peripheral artery diseases to expedite growth
  • 15.5.5 ARGENTINA
    • 15.5.5.1 Increasing prevalence of peripheral artery diseases to support market growth
  • 15.5.6 REST OF LATIN AMERICA
• 15.6 MIDDLE EAST & AFRICA
  • 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 15.6.2 GCC COUNTRIES
    • 15.6.2.1 Rising cases of hypertension and associated cardiovascular diseases to drive market
  • 15.6.3 REST OF MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE

• 16.1 INTRODUCTION
• 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
• 16.3 REVENUE ANALYSIS
• 16.4 MARKET SHARE ANALYSIS
• 16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 16.5.1 STARS
  • 16.5.2 EMERGING LEADERS
  • 16.5.3 PERVASIVE PLAYERS
  • 16.5.4 PARTICIPANTS
  • 16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 16.5.5.1 Company footprint
    • 16.5.5.2 Type footprint
    • 16.5.5.3 Region footprint
• 16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 16.6.1 PROGRESSIVE COMPANIES
  • 16.6.2 DYNAMIC COMPANIES
  • 16.6.3 RESPONSIVE COMPANIES
  • 16.6.4 STARTING BLOCKS
  • 16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 16.7 BRAND/PRODUCT COMPARISON
• 16.8 COMPANY VALUATION AND FINANCIAL METRICS
  • 16.8.1 FINANCIAL METRICS
  • 16.8.2 COMPANY VALUATION
• 16.9 COMPETITIVE SCENARIO
  • 16.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 16.9.2 DEALS

17 COMPANY PROFILES

• 17.1 KEY PLAYERS
  • 17.1.1 BOSTON SCIENTIFIC CORPORATION
    • 17.1.1.1 Business overview
    • 17.1.1.2 Products offered
    • 17.1.1.3 Recent developments
      • 17.1.1.3.1 Product approvals
      • 17.1.1.3.2 Deals
      • 17.1.1.3.3 Other developments
    • 17.1.1.4 MnM view
      • 17.1.1.4.1 Right to win
      • 17.1.1.4.2 Strategic choices
      • 17.1.1.4.3 Weaknesses and competitive threats
  • 17.1.2 MEDTRONIC
    • 17.1.2.1 Business overview
    • 17.1.2.2 Products offered
    • 17.1.2.3 Recent developments
      • 17.1.2.3.1 Product launches & product approvals
      • 17.1.2.3.2 Deals
    • 17.1.2.4 MnM view
      • 17.1.2.4.1 Right to win
      • 17.1.2.4.2 Strategic choices
      • 17.1.2.4.3 Weaknesses and competitive threats
  • 17.1.3 ABBOTT
    • 17.1.3.1 Business overview
    • 17.1.3.2 Products offered
    • 17.1.3.3 Recent developments
      • 17.1.3.3.1 Product launches
      • 17.1.3.3.2 Deals
    • 17.1.3.4 MnM view
      • 17.1.3.4.1 Right to win
      • 17.1.3.4.2 Strategic choices made
      • 17.1.3.4.3 Weaknesses and competitive threats
  • 17.1.4 BECTON, DICKINSON AND COMPANY
    • 17.1.4.1 Business overview
    • 17.1.4.2 Products offered
    • 17.1.4.3 Recent developments
      • 17.1.4.3.1 Product launches and product approvals
      • 17.1.4.3.2 Deals
      • 17.1.4.3.3 Other developments
    • 17.1.4.4 MnM view
      • 17.1.4.4.1 Right to win
      • 17.1.4.4.2 Strategic choices
      • 17.1.4.4.3 Weaknesses and competitive threats
  • 17.1.5 TERUMO CORPORATION
    • 17.1.5.1 Business overview
    • 17.1.5.2 Products offered
    • 17.1.5.3 Recent developments
      • 17.1.5.3.1 Product launches
    • 17.1.5.4 MnM view
      • 17.1.5.4.1 Right to win
      • 17.1.5.4.2 Strategic choices
      • 17.1.5.4.3 Weaknesses and competitive threats
  • 17.1.6 B. BRAUN SE
    • 17.1.6.1 Business overview
    • 17.1.6.2 Products offered
    • 17.1.6.3 Recent developments
      • 17.1.6.3.1 Product approvals
  • 17.1.7 MERIT MEDICAL SYSTEMS
    • 17.1.7.1 Business overview
    • 17.1.7.2 Products offered
    • 17.1.7.3 Recent developments
      • 17.1.7.3.1 Product launches
      • 17.1.7.3.2 Deals
  • 17.1.8 PENUMBRA, INC.
    • 17.1.8.1 Business overview
    • 17.1.8.2 Products offered
    • 17.1.8.3 Recent developments
      • 17.1.8.3.1 Product launches and product approvals
  • 17.1.9 KONINKLIJKE PHILIPS NV
    • 17.1.9.1 Business overview
    • 17.1.9.2 Products offered
    • 17.1.9.3 Recent developments
      • 17.1.9.3.1 Product approvals
      • 17.1.9.3.2 Deals
  • 17.1.10 STRYKER
    • 17.1.10.1 Business overview
    • 17.1.10.2 Products offered
      • 17.1.10.2.1 Deals
  • 17.1.11 CORDIS
    • 17.1.11.1 Business overview
    • 17.1.11.2 Products offered
    • 17.1.11.3 Recent developments
      • 17.1.11.3.1 Product approvals
      • 17.1.11.3.2 Deals
      • 17.1.11.3.3 Other developments
  • 17.1.12 COOK
    • 17.1.12.1 Business overview
    • 17.1.12.2 Products offered
    • 17.1.12.3 Recent developments
      • 17.1.12.3.1 Deals
  • 17.1.13 W. L. GORE & ASSOCIATES, INC.
    • 17.1.13.1 Business overview
    • 17.1.13.2 Products offered
    • 17.1.13.3 Recent developments
      • 17.1.13.3.1 Product approvals
  • 17.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD.
    • 17.1.14.1 Business overview
    • 17.1.14.2 Products offered
  • 17.1.15 IVASCULAR
    • 17.1.15.1 Business overview
    • 17.1.15.2 Products offered
  • 17.1.16 BIOTRONIK
    • 17.1.16.1 Business overview
    • 17.1.16.2 Products offered
    • 17.1.16.3 Recent developments
      • 17.1.16.3.1 Product launches
  • 17.1.17 ENDOLOGIX
    • 17.1.17.1 Business overview
    • 17.1.17.2 Products offered
  • 17.1.18 ENDOCOR GMBH & CO., KG
    • 17.1.18.1 Business overview
    • 17.1.18.2 Products offered
• 17.2 OTHER PLAYERS
  • 17.2.1 MERIL LIFE SCIENCES PVT. LTD.
  • 17.2.2 ALVIMEDICA
  • 17.2.3 CARDIONOVUM GMBH
  • 17.2.4 SMT
  • 17.2.5 MEDINOL
  • 17.2.6 ANDRAMED GMBH
  • 17.2.7 REX MEDICAL
  • 17.2.8 QMD INC.
  • 17.2.9 BROSMED MEDICAL CO., LTD.
  • 17.2.10 ELIXIR MEDICAL

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS